Immatics Proprietary Target Selected for the Development of Cancer Immunotherapies
Tuebingen and Munich, Germany, December 21, 2017 - Immatics, a leading company in the field of cancer immunotherapy, announced today that Roche has exercised its option under the existing discovery, development and commercialization agreement between the companies to exclusively license from Immatics a proprietary immunotherapy target for further development and commercialization in oncology.
The target was identified and validated using Immatics’ world-leading XPRESIDENT® technology platform. Successful development and subsequent commercialization of cancer immunotherapies directed against this target would trigger payment of additional development and sales milestones by Roche to Immatics, as well as royalty payments on worldwide net sales.
Dr Harpreet Singh, Chief Scientific Officer at Immatics, said: “We are very pleased to see that a novel immunotherapy directed against an Immatics target is progressed towards the clinic. This is yet another validation from a global leader in oncology of the quality and potential of the XPRESIDENT® platform and Immatics’ targets for cancer therapy.”
About XPRESIDENT® Technology
XPRESIDENT® is the most sensitive, accurate and highest-throughput technology capable of identifying targets in virtually any type of cancer. This proprietary technology provides novel, highly-specific, and safe cancer targets that are pivotal for developing a range of powerful immunotherapies with the potential to cure cancer. The cancer targets identified by XPRESIDENT® are peptides presented by human leukocyte antigen (HLA) receptors on the surface of tumor cells. Classical antibody and CAR-T therapies are restricted to cell surface proteins, which constitute only about 20-25% of all available targets on a solid tumor. XPRESIDENT® unlocks all intracellular antigens, increasing the target space by more than 4-fold.
Download Press Release as PDF here